- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.
Novo Nordisk Reports on CagriSema Trials for Type 2 Diabetes and Obesity
What happened
Novo Nordisk released topline results from two Phase 3 trials evaluating CagriSema, an investigational combination therapy of cagrilintide and semaglutide. In the REIMAGINE 5 trial, CagriSema was found to be noninferior to tirzepatide regarding HbA1c reduction, while demonstrating superiority in weight loss. Furthermore, the REDEFINE 9 trial showed that CagriSema 1mg/1mg led to an average weight reduction of 21% compared to 2% for placebo.
From empr.com
Why it matters
The announcement adds to the intense competition in the weight loss market between pharmaceutical companies. The data compares the new combination therapy directly against tirzepatide, a leading drug in the class. This development impacts the competitive landscape of obesity and diabetes treatments.
Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes. Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
From empr.com
Who's involved
- Novo NordiskDanish pharmaceutical company conducting trials for a new combination therapy.